Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma
Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported. We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000 mg/m 2 and c...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2006-08, Vol.100 (8), p.1463-1465 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1465 |
|---|---|
| container_issue | 8 |
| container_start_page | 1463 |
| container_title | Respiratory medicine |
| container_volume | 100 |
| creator | Imen, Aissa Amal, Khattab Ines, Zendah Sameh, El Farhati Fethi, El Mekki Habib, Ghedira |
| description | Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported.
We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000
mg/m
2 and cisplatin 75
mg/m
2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis. |
| doi_str_mv | 10.1016/j.rmed.2005.11.027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1035045485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611105005184</els_id><sourcerecordid>2744988441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-90e87e88d143c14807278d41adcbfc7ac3ca02cabb76e185e13f8c609e963e303</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCH-CALKEeE2Zi50viQisolSpxAYmb5UwmrVdOvNhJq_57Eu0KbpzmMM_7zugR4h1CjoDVx30eR-7zAqDMEXMo6hdih6UqMgWVfil20JY6qxDxTJyntAeAVmt4Lc6w0kpjrXbi19XifViS7DmOdg7JJWlTCuTszL18cvODvOeR3Gw7N7GcHzjaw7McQpRTmLI0Wu8zYu-lX6Z7STaSm8Jo34hXg_WJ357mhfj59cuP62_Z3feb2-vPdxnpspqzFripuWl61IpQN1AXddNrtD11A9WWFFkoyHZdXTE2JaMaGqqg5bZSrEBdiA_H3kMMvxdOs9mHJU7rSYOgStClbsqVKo4UxZBS5MEcohttfF4hs8k0e7PJNJtMg2hWmWvo_al66bbd38jJ3gpcngCbyPoh2olc-sfVrYYCt-ufjhyvIh4dR5PI8UTcu8g0mz64__3xB1oDkwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1035045485</pqid></control><display><type>article</type><title>Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Imen, Aissa ; Amal, Khattab ; Ines, Zendah ; Sameh, El Farhati ; Fethi, El Mekki ; Habib, Ghedira</creator><creatorcontrib>Imen, Aissa ; Amal, Khattab ; Ines, Zendah ; Sameh, El Farhati ; Fethi, El Mekki ; Habib, Ghedira</creatorcontrib><description>Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported.
We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000
mg/m
2 and cisplatin 75
mg/m
2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2005.11.027</identifier><identifier>PMID: 16434173</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Antimetabolites, Antineoplastic - adverse effects ; Baldness ; Biological and medical sciences ; Blister - chemically induced ; Bullous dermatosis ; Bullous diseases of the skin ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Chemotherapy ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Dermatology ; Drug Eruptions - etiology ; Gemcitabine ; Humans ; Legs ; Lung carcinoma ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; Pneumology ; Skin diseases ; Toxicity ; Tumors of the respiratory system and mediastinum</subject><ispartof>Respiratory medicine, 2006-08, Vol.100 (8), p.1463-1465</ispartof><rights>2005 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-90e87e88d143c14807278d41adcbfc7ac3ca02cabb76e185e13f8c609e963e303</citedby><cites>FETCH-LOGICAL-c456t-90e87e88d143c14807278d41adcbfc7ac3ca02cabb76e185e13f8c609e963e303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rmed.2005.11.027$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17940215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16434173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imen, Aissa</creatorcontrib><creatorcontrib>Amal, Khattab</creatorcontrib><creatorcontrib>Ines, Zendah</creatorcontrib><creatorcontrib>Sameh, El Farhati</creatorcontrib><creatorcontrib>Fethi, El Mekki</creatorcontrib><creatorcontrib>Habib, Ghedira</creatorcontrib><title>Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported.
We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000
mg/m
2 and cisplatin 75
mg/m
2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis.</description><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Baldness</subject><subject>Biological and medical sciences</subject><subject>Blister - chemically induced</subject><subject>Bullous dermatosis</subject><subject>Bullous diseases of the skin</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Chemotherapy</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Dermatology</subject><subject>Drug Eruptions - etiology</subject><subject>Gemcitabine</subject><subject>Humans</subject><subject>Legs</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pneumology</subject><subject>Skin diseases</subject><subject>Toxicity</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EotvCH-CALKEeE2Zi50viQisolSpxAYmb5UwmrVdOvNhJq_57Eu0KbpzmMM_7zugR4h1CjoDVx30eR-7zAqDMEXMo6hdih6UqMgWVfil20JY6qxDxTJyntAeAVmt4Lc6w0kpjrXbi19XifViS7DmOdg7JJWlTCuTszL18cvODvOeR3Gw7N7GcHzjaw7McQpRTmLI0Wu8zYu-lX6Z7STaSm8Jo34hXg_WJ357mhfj59cuP62_Z3feb2-vPdxnpspqzFripuWl61IpQN1AXddNrtD11A9WWFFkoyHZdXTE2JaMaGqqg5bZSrEBdiA_H3kMMvxdOs9mHJU7rSYOgStClbsqVKo4UxZBS5MEcohttfF4hs8k0e7PJNJtMg2hWmWvo_al66bbd38jJ3gpcngCbyPoh2olc-sfVrYYCt-ufjhyvIh4dR5PI8UTcu8g0mz64__3xB1oDkwg</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Imen, Aissa</creator><creator>Amal, Khattab</creator><creator>Ines, Zendah</creator><creator>Sameh, El Farhati</creator><creator>Fethi, El Mekki</creator><creator>Habib, Ghedira</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>20060801</creationdate><title>Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma</title><author>Imen, Aissa ; Amal, Khattab ; Ines, Zendah ; Sameh, El Farhati ; Fethi, El Mekki ; Habib, Ghedira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-90e87e88d143c14807278d41adcbfc7ac3ca02cabb76e185e13f8c609e963e303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Baldness</topic><topic>Biological and medical sciences</topic><topic>Blister - chemically induced</topic><topic>Bullous dermatosis</topic><topic>Bullous diseases of the skin</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Chemotherapy</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Dermatology</topic><topic>Drug Eruptions - etiology</topic><topic>Gemcitabine</topic><topic>Humans</topic><topic>Legs</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pneumology</topic><topic>Skin diseases</topic><topic>Toxicity</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imen, Aissa</creatorcontrib><creatorcontrib>Amal, Khattab</creatorcontrib><creatorcontrib>Ines, Zendah</creatorcontrib><creatorcontrib>Sameh, El Farhati</creatorcontrib><creatorcontrib>Fethi, El Mekki</creatorcontrib><creatorcontrib>Habib, Ghedira</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imen, Aissa</au><au>Amal, Khattab</au><au>Ines, Zendah</au><au>Sameh, El Farhati</au><au>Fethi, El Mekki</au><au>Habib, Ghedira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>100</volume><issue>8</issue><spage>1463</spage><epage>1465</epage><pages>1463-1465</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported.
We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000
mg/m
2 and cisplatin 75
mg/m
2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16434173</pmid><doi>10.1016/j.rmed.2005.11.027</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2006-08, Vol.100 (8), p.1463-1465 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_journals_1035045485 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Antimetabolites, Antineoplastic - adverse effects Baldness Biological and medical sciences Blister - chemically induced Bullous dermatosis Bullous diseases of the skin Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Dermatology Drug Eruptions - etiology Gemcitabine Humans Legs Lung carcinoma Lung Neoplasms - drug therapy Male Medical sciences Pneumology Skin diseases Toxicity Tumors of the respiratory system and mediastinum |
| title | Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T10%3A50%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bullous%20dermatosis%20associated%20with%20gemcitabine%20therapy%20for%20non-small-cell%20lung%20carcinoma&rft.jtitle=Respiratory%20medicine&rft.au=Imen,%20Aissa&rft.date=2006-08-01&rft.volume=100&rft.issue=8&rft.spage=1463&rft.epage=1465&rft.pages=1463-1465&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2005.11.027&rft_dat=%3Cproquest_cross%3E2744988441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1035045485&rft_id=info:pmid/16434173&rft_els_id=S0954611105005184&rfr_iscdi=true |